. >> medtronic is one of the devicemakers.ng and health care is no exception. medtronic has gotten regulatory confirmation for five a.i. efforts that -- a.i. products that they are doing including an a.i. generative system for diabetes, which is mini med and they have an a.i. product for endoscopy, so lots of ways to do it. in fact, just last quarter you heard about medtronic talking about the adoption of its a.i. surgical planning for spinal surgery that has been shown to improve outcomes for spinal surgery, so this is one of the plays where you see an industry where, you know, demand is nearly unlimited. resources are very limited. a.i. could actually have an enormous impact on driving demand and, quite frankly, if you look at this stock on a forward, you know, p/e basis it's trading at 16 times very attractive with strong and stable margins. >> michael? >> i've owned it for a long time. i like they've had consistent and positive sales growth. once again i agree with gina, and i think you're going to see not only medtronic b

one of my favorite medical device companies medtronic. it's been getting approvals i think can lead to big numbers. this one is turning into a winner. we get results from the footwear champ deckers. they are selling the hottest athletic shoe, save maybe on. i expect one great quarter from deckard's. people have been against it and i think that is ill-advised. one of those that's going to report on friday and that is into it. they own quickbooks, mail chimp, credit karma and turbotax. i think into it had a great tech season. small businesses can stay away from quickbooks. and off press chain delivered a set of numbers. the consumer loves them both. there's room for both i think as far as i'm concerned. 20 of room because that is exactly the segment that we find more people in than ever. a lot to love next week. for many it is really bad. i'm not kidding. i hope we clear out the short- term traders for nvidia and end up with a more reliable, steady believing shareholder base. let's go to trey in texas. >> for 50 years oscar meyer has claime

over to you with medtronic. >> well, the math here stinks. is really an ozempic casualty. this is a health care company that, where the to ozempic fierce overblown. the stock's been acting like -- fierce overblown. it's been acting like you're going going to need any cardiac care anymore. i think there's going to be tremendous upside in this stock over the course of the next 12 months. again, ozempic fears are totally overblown here. stuart tower interesting. salesforce you like that. >> this is your mission critical software for businesses, specific create small businesses. and when you look at this, here's a company that has, i think, over 90% of their revenues recurring, they have, like, a 92, 93% retention rate on their customers, high margin business. they're integrating a.i. to help businesses become even more efficient, even more productive. they report after the bell today. i think you're going to see a god quarter. a. stuart: mark, thanks very much, indeed. we have got to check the yield on the 10-year treasury. it's going up. up as